Mostrar el registro sencillo del documento

dc.creatorZhu, Zhe
dc.creatorCai, Ting
dc.creatorFan, Lingyan
dc.creatorLou, Kehong
dc.creatorHua, Xin
dc.creatorHuang, Zuoan
dc.creatorGao, Guosheng
dc.date.accessioned2020-07-21T19:38:57Z
dc.date.available2020-07-21T19:38:57Z
dc.date.created2020
dc.identifier.issn1201-9712spa
dc.identifier.otherhttps://doi.org/10.1016/j.ijid.2020.04.041spa
dc.identifier.urihttp://hdl.handle.net/20.500.12010/10888
dc.description.abstractObjective: To explore the clinical value of immune-inflammatory markers to assess the severity of coronavirus disease 2019 (COVID-19). Methods: 127 consecutive hospitalized patients with confirmed COVID-19 were enrolled in this study, and classified into non-severe and severe groups. Demographics, symptoms, underlying diseases and laboratory data were collected and assessed for predictive value. Results: Of 127 COVID-19 patients, 16 cases (12.60%) were classified into the severe group. High level of interleukin-6 (IL-6), C-reaction protein (CRP) and hypertension were independent risk factors for the severity of COVID-19. The risk model based on IL-6, CRP and hypertension had the highest area under the receiver operator characteristic curve (AUROC). Additionally, the baseline IL-6 was positively correlated with other immune-inflammatory parameters and the dynamic change of IL-6 in the severe cases were parallel to the amelioration of the disease. Conclusion: Our study showed that high level of IL-6, CRP and hypertension were independent risk factors for assessing the severity of COVID-19. The risk model established upon IL-6, CRP and hypertension had the highest predictability in this study. Besides, IL-6 played a pivotal role in the severity of COVID-19 and had a potential value for monitoring the process of severe casesspa
dc.format.extent8 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.publisherScience Directeng
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectCOVID-19spa
dc.subjectSARS-CoV-2spa
dc.subjectImmune-inflammatory parametersspa
dc.subjectCytokine stormspa
dc.subjectIL-6spa
dc.titleClinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019spa
dc.type.localArtículospa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.identifier.doihttps://doi.org/10.1016/j.ijid.2020.04.041spa


Archivos en el documento

Thumbnail

Este documento aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del documento